Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Tax Provisions (2023 - 2025)

Axsome Therapeutics' Tax Provisions history spans 3 years, with the latest figure at $460000.0 for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 441.18% to $460000.0 in Q4 2025 year-over-year; TTM through Mar 2026 was -$540000.0, a 735.29% decrease, with the full-year FY2025 number at -$500000.0, down 688.24% from a year prior.
  • Tax Provisions hit $460000.0 in Q4 2025 for Axsome Therapeutics, up from -$1.0 million in the prior quarter.
  • Over the last five years, Tax Provisions for AXSM hit a ceiling of $2.6 million in Q1 2023 and a floor of -$1.0 million in Q2 2025.
  • Historically, Tax Provisions has averaged $77428.6 across 3 years, with a median of -$325000.0 in 2023.
  • Biggest five-year swings in Tax Provisions: skyrocketed 126.15% in 2024 and later skyrocketed 441.18% in 2025.
  • Tracing AXSM's Tax Provisions over 3 years: stood at -$325000.0 in 2023, then skyrocketed by 126.15% to $85000.0 in 2024, then skyrocketed by 441.18% to $460000.0 in 2025.
  • Business Quant data shows Tax Provisions for AXSM at $460000.0 in Q4 2025, -$1.0 million in Q2 2025, and $85000.0 in Q4 2024.